NCT01666080View on ClinicalTrials.gov

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Hematologic DisordersHemoglobinopathiesImmunodeficiencies
Interventions
DRUG

Busulfan

0.4 mg/kg (0.5 mg/kg if \<4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.

DRUG

Fludarabine

40 mg/m\^2 intravenously (IV) over 1 hour on days -6 through -2.

RADIATION

Total body irradiation

200 cGy on Day -1

BIOLOGICAL

Stem cell transplant

stem cell infusion on day 0

DRUG

Keppra

Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.

Trial Locations (1)

55455

RECRUITING

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER